The FDA recently approved Nevro (NVRO) treatment for chronic pain from Painful Diabetic Neuropathy (PDN). The treatment is called HFX™ and is now the only spinal cord stimulation system treatment for PDN that is approved by the FDA. Keith Grossman, Chairman and CEO of Nevro, discusses HFX™, as well as what this treatment means for diabetic patients. Nevro stock also hit an all-time high in December 2020. Tune in to find out more.
The Watch List
22 Jul 2021
SHARE
The Watch List
28 Apr 2022
The Watch List
13 May 2022
Next Gen Investing
27 Jun 2022
Market On Close
07 Jul 2022
The Watch List
20 May 2022
Trading 360
23 Jun 2022